Background: Urinary bladder cancer (BC) is the seventh mostcommon cancer worldwide with the highest incidence rates inWestern Europe, North America, and Australia. The mostcommon type of BC is urothelial carcinoma (UC), which representsa significant cause of morbidity and mortality. Objective: The aim of the study was to evaluate the prognosticvalue of CD24, SOX2, and Nanog in UC cases and the correlatiowith recurrence and survival. Materials and Methods: In this study, the authors investigatedthe expression of CD24, SOX2, and Nanog in 80 patients withurinary BC. The clinical significance of the markers was evaluatedby assessing the correlation with the clinicopathologic parameters and prognosis. Results: The CD24 expression was positive in 62.5% of theBC patients, there was a significant association between CD24expression and high grade and stage and lymphovascular invasion(LVI), P (0.002, 0.0010, and 0.001). SOX2 was expressedin 60 patients (75%), the expression was significantly associatewith age, stage, grade, LVI, lymph node, and smoking, P (0.016,0.01, <0.001, 0.003, 0.036, and 0.002), respectively. Nanog expressionwas positive in 60% of the BC patients. There wasa significant association between Nanog expression and age, high grade, high stage, and LVI (P=0.016, <0.001, and 0.003),respectively. Conclusions: A significant relation between CD24, SOX2, andNanog with the invasive potential of UC. This increase in expressionof the 3 markers with the grades and stages of UCsuggests that they can play a role in the development of UC, sothey can be used in targeted therapy in the future.